DK2349259T3 - Mitose-inhibitorer til forøgelse af apoptose i terapi - Google Patents
Mitose-inhibitorer til forøgelse af apoptose i terapi Download PDFInfo
- Publication number
- DK2349259T3 DK2349259T3 DK09748884.5T DK09748884T DK2349259T3 DK 2349259 T3 DK2349259 T3 DK 2349259T3 DK 09748884 T DK09748884 T DK 09748884T DK 2349259 T3 DK2349259 T3 DK 2349259T3
- Authority
- DK
- Denmark
- Prior art keywords
- inhibitor
- cells
- cancer
- mitosis
- use according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Claims (15)
1. '161 KSP-inhibitor til anvendelse i behandlingen af patogene celler i en tilstand af '161 KSP-inhibitor-induceret mitotisk arrest, til forøgelse af apoptose af cellerne, hvor '161 KSP-inhibitoren er valgt fra 2-(3-aminopropyl)-5-(3-fluorphenyl)-N-(2-methoxyethyl)-N-methyl-2-phenyl-l,3,4-thiadiazol-3(2H)-carboxamid, 2-(3-aminopropyl)-5-(3-fluorphenyl)-N-methoxy-N-methyl-2-phenyl-l,3,4-thiadiazol-3(2H)-carboxamid, 2-(3-aminopropyl)-5-(2,5-difluorphenyl)-N-methoxy-N-methyl-2-phenyl-l,3,4-thiadiazol-3(2H)-carboxamid, (S)-2-(3-aminopropyl)-5-(2,5-difluorphenyl)-N-methoxy-N-methyl-2-phenyl-l,3,4-thiadiazol-3(2H)-carboxamid, (R)-2-(3-aminopropyl)-5-(2,5-difluorphenyl)-N-methoxy-N-methyl-2-phenyl-l ,3,4-thiadiazol-3(2H)-carboxamid, og 2-(3-aminopropyl)-5-(2,5-difluorphenyl)-N-hydroxy-N-methyl-2-phenyl-l,3,4-thiadiazol-3(2H)-carboxamid.
2. Inhibitoren til anvendelse ifølge krav 1, der er den samme som inhibitoren der har induceret mitotisk arrest.
3. Inhibitoren til anvendelse ifølge krav 1 eller 2, der er (S)-2-(3-aminopropyl)-5-(2,5-difluorphenyl)-N-methoxy-N-methyl-2-phenyl-l,3,4-thiadiazol-3(2H)-carboxamid.
4. Inhibitoren til anvendelse ifølge et hvilket som helst af kravene 1 til 3, hvor de patogene celler er cancerceller.
5. Inhibitoren til anvendelse ifølge et hvilket som helst af kravene 1 til 4, hvor de patogene celler er hæmatologiske tumorceller.
6. Inhibitoren til anvendelse ifølge et hvilket som helst af kravene 1 til 5, hvor de patogene celler er valgt fra lymfomer, leukæmi- og multipel myelomceller.
7. Inhibitoren til anvendelse ifølge et hvilket som helst af kravene 1 til 4, hvor de patogene celler er faste tumorceller.
8. Inhibitoren til anvendelse ifølge et hvilket som helst af kravene 1 til 4 eller 7, hvor de patogene celler er valgt fra tumorceller fra huden, bryst, hjerne, cervikal carcinom og testikel-carcinomceller.
9. Inhibitoren til anvendelse ifølge et hvilket som helst af kravene 1 til 4 eller 7, hvor de patogene celler er valgt fra brystcancer, colorektalcancer, ikke-småcellet lungecancer, bugspytkirtelcancer, blærecancer, spytkirtelcancer (adenoid cystisk), esophagealcancer, mesotheliomcancer, og blandet småcellet lungecancer/ikke-småcellet lungecancer.
10. Inhibitoren til anvendelse ifølge et hvilket som helst af kravene 1 til 9, hvor inhibitoren er til administration ved den maksimalt tolerable dosis.
11. Inhibitoren til anvendelse ifølge et hvilket som helst af kravene 3 til 10, hvor den maksimalt tolerable dosis er 1,25 mg/m2/dag.
12. Inhibitoren til anvendelse ifølge et hvilket som helst af kravene 1 til 11, hvor '161-inhibitoren til administration administreres 12 til 60 timer efter '161-inhibitoren der inducerer mitotisk arrest.
13. Inhibitoren til anvendelse ifølge et hvilket som helst af kravene 1 til 12, hvor '161-inhibitoren til administration administreres 24 til 48 timer efter '161-inhibitoren der inducerer mitotisk arrest.
14. Inhibitoren til anvendelse ifølge et hvilket som helst af kravene 1 til 13, hvor '161-inhibitoren administreres i en cyklus fra 11 til 24 dage.
15. Inhibitoren til anvendelse ifølge et hvilket som helst af kravene 1 til 14, hvor '161-inhibitoren administreres i en cyklus fra 14 til 21 dage.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10608608P | 2008-10-16 | 2008-10-16 | |
| PCT/US2009/061106 WO2010045624A1 (en) | 2008-10-16 | 2009-10-16 | Inhibitors of mitosis for increasing apoptosis in therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2349259T3 true DK2349259T3 (da) | 2016-02-29 |
Family
ID=41508147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK09748884.5T DK2349259T3 (da) | 2008-10-16 | 2009-10-16 | Mitose-inhibitorer til forøgelse af apoptose i terapi |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP2349259B1 (da) |
| JP (2) | JP5749170B2 (da) |
| CN (2) | CN102256603B (da) |
| AU (1) | AU2009305588B2 (da) |
| BR (1) | BRPI0920878A2 (da) |
| CA (1) | CA2741069C (da) |
| CY (1) | CY1117281T1 (da) |
| DK (1) | DK2349259T3 (da) |
| ES (1) | ES2565778T3 (da) |
| HK (1) | HK1154813A1 (da) |
| HR (1) | HRP20160267T1 (da) |
| HU (1) | HUE027170T2 (da) |
| IL (1) | IL212413A (da) |
| PL (1) | PL2349259T3 (da) |
| RS (1) | RS54647B1 (da) |
| RU (1) | RU2519145C2 (da) |
| SI (1) | SI2349259T1 (da) |
| SM (1) | SMT201600073B (da) |
| UA (1) | UA106214C2 (da) |
| WO (1) | WO2010045624A1 (da) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA106214C2 (ru) * | 2008-10-16 | 2014-08-11 | Эррей Биофарма Инк. | Ингибиторы митоза для интенсификации процесса апоптоза при терапии |
| TWI427054B (zh) * | 2012-01-20 | 2014-02-21 | Nat Univ Chung Hsing | A pharmaceutical composition for inhibiting and treating a lung tumor and inhibiting an inflammatory reaction and a method for preparing the same |
| IN2015KN00676A (da) * | 2012-08-13 | 2015-07-17 | Array Biopharma Inc | |
| US20150045391A1 (en) | 2013-08-08 | 2015-02-12 | Array Biopharma Inc | Filanesib combined with pomalidomide displays enhanced anti-tumor activity |
| CN107636159B (zh) | 2015-02-04 | 2022-06-14 | 百时美施贵宝公司 | 选择治疗性分子的方法 |
| JP7340240B2 (ja) * | 2019-08-26 | 2023-09-07 | 学校法人関西医科大学 | 細胞又は組織にアポトーシスを誘導する方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1816543B (zh) * | 2003-06-05 | 2011-01-19 | 赞塔里斯有限公司 | 具有细胞凋亡诱导效应的吲哚衍生物 |
| US7449486B2 (en) * | 2004-10-19 | 2008-11-11 | Array Biopharma Inc. | Mitotic kinesin inhibitors and methods of use thereof |
| UA106214C2 (ru) * | 2008-10-16 | 2014-08-11 | Эррей Биофарма Инк. | Ингибиторы митоза для интенсификации процесса апоптоза при терапии |
-
2009
- 2009-10-16 UA UAA201106118A patent/UA106214C2/ru unknown
- 2009-10-16 DK DK09748884.5T patent/DK2349259T3/da active
- 2009-10-16 WO PCT/US2009/061106 patent/WO2010045624A1/en active Application Filing
- 2009-10-16 EP EP09748884.5A patent/EP2349259B1/en active Active
- 2009-10-16 SI SI200931379T patent/SI2349259T1/sl unknown
- 2009-10-16 RS RS20160175A patent/RS54647B1/en unknown
- 2009-10-16 CN CN200980150472.2A patent/CN102256603B/zh active Active
- 2009-10-16 RU RU2011119427/15A patent/RU2519145C2/ru active
- 2009-10-16 CN CN201510222295.1A patent/CN104958292B/zh active Active
- 2009-10-16 ES ES09748884.5T patent/ES2565778T3/es active Active
- 2009-10-16 BR BRPI0920878A patent/BRPI0920878A2/pt not_active Application Discontinuation
- 2009-10-16 JP JP2011532305A patent/JP5749170B2/ja active Active
- 2009-10-16 PL PL09748884T patent/PL2349259T3/pl unknown
- 2009-10-16 CA CA2741069A patent/CA2741069C/en active Active
- 2009-10-16 AU AU2009305588A patent/AU2009305588B2/en active Active
- 2009-10-16 HU HUE09748884A patent/HUE027170T2/hu unknown
-
2011
- 2011-04-17 IL IL212413A patent/IL212413A/en active IP Right Grant
- 2011-09-01 HK HK11109252.1A patent/HK1154813A1/zh unknown
-
2014
- 2014-05-19 JP JP2014102987A patent/JP2014144979A/ja active Pending
-
2016
- 2016-03-10 CY CY20161100206T patent/CY1117281T1/el unknown
- 2016-03-14 SM SM201600073T patent/SMT201600073B/xx unknown
- 2016-03-14 HR HRP20160267TT patent/HRP20160267T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CY1117281T1 (el) | 2017-04-26 |
| EP2349259A1 (en) | 2011-08-03 |
| HUE027170T2 (hu) | 2016-10-28 |
| AU2009305588B2 (en) | 2015-08-13 |
| CN102256603B (zh) | 2015-06-03 |
| JP5749170B2 (ja) | 2015-07-15 |
| CN102256603A (zh) | 2011-11-23 |
| EP2349259B1 (en) | 2015-12-23 |
| HK1154813A1 (zh) | 2012-05-04 |
| SI2349259T1 (sl) | 2016-03-31 |
| AU2009305588A1 (en) | 2010-04-22 |
| WO2010045624A1 (en) | 2010-04-22 |
| JP2014144979A (ja) | 2014-08-14 |
| HRP20160267T1 (hr) | 2016-04-08 |
| JP2012505924A (ja) | 2012-03-08 |
| PL2349259T3 (pl) | 2016-07-29 |
| UA106214C2 (ru) | 2014-08-11 |
| IL212413A (en) | 2015-08-31 |
| SMT201600073B (it) | 2016-04-29 |
| CN104958292B (zh) | 2018-10-16 |
| CA2741069C (en) | 2017-08-22 |
| RU2519145C2 (ru) | 2014-06-10 |
| CA2741069A1 (en) | 2010-04-22 |
| RU2011119427A (ru) | 2012-11-27 |
| ES2565778T3 (es) | 2016-04-06 |
| RS54647B1 (en) | 2016-08-31 |
| CN104958292A (zh) | 2015-10-07 |
| IL212413A0 (en) | 2011-06-30 |
| BRPI0920878A2 (pt) | 2015-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20180338958A1 (en) | Method of treatment using inhibitors of mitosis | |
| DK2349259T3 (da) | Mitose-inhibitorer til forøgelse af apoptose i terapi | |
| RU2627841C2 (ru) | Комбинация ингибиторов чекпойнт-киназы 1 и ингибиторов киназы wee 1 | |
| ES2600304T3 (es) | Tratamiento de tumores sólidos de riñón con un derivado de rapamicina | |
| ES2384789T3 (es) | Combinación de un análogo de epotilona y agentes quimioterapéuticos para el tratamiento de enfermedades proliferativas | |
| Zhuang et al. | Pien Tze Huang inhibits tumor cell proliferation and promotes apoptosis via suppressing the STAT3 pathway in a colorectal cancer mouse model | |
| Liao et al. | Cordycepin reverses cisplatin resistance in non-small cell lung cancer by activating AMPK and inhibiting AKT signaling pathway | |
| CN104997808A (zh) | 用于治疗癌症的方法和组合物 | |
| Huang et al. | Dihydroartemisinin potentiates the cytotoxic effect of temozolomide in rat C6 glioma cells | |
| Achari et al. | Chebulagic acid synergizes the cytotoxicity of doxorubicin in human hepatocellular carcinoma through COX-2 dependant modulation of MDR-1 | |
| JP2022506829A (ja) | エリブリンと選択的ｃｄｋ４／６阻害剤との組合せを使用する癌の処置のための治療レジメン | |
| KR20150136074A (ko) | 저용량 이리노테칸염산염 수화물을 함유하는 항종양제 | |
| US20160128988A1 (en) | Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor | |
| US20120329841A1 (en) | Treating cancer with desthiazolyl ritonavir | |
| KR101847252B1 (ko) | 이리노테칸염산염 수화물을 함유하는 항종양제 | |
| Zhu et al. | HSP90: A promising target for NSCLC treatments | |
| WO2023230656A1 (en) | Ion channel inhibitor combination treatment for cancer | |
| ES2349763T3 (es) | Tratamiento de enfermedades de tumor sólido con combinaciones que comprenden imatinib y un inhibidor de bomba de eflujo. | |
| WO2005000292A1 (en) | Cancer treatment with epothilones | |
| Tech et al. | Sequential release of Epigallocatechin gallate and Paclitaxel from PLGA-Casein core/shell nanoparticles sensitizes drug-resistant breast cancer cells | |
| Ying et al. | In vitro and in vivo efficacy of the novel Hsp90 inhibitor STA-9090 and its synergy with paclitaxel |